Premium
Treatment of vascular and soft‐tissue sarcomas in dogs using an alternating protocol of ifosfamide and doxorubicin
Author(s) -
Payne S. E.,
Rassnick K. M.,
Northrup N. C.,
Kristal O.,
Chretin J. D.,
Cotter S. M.,
Kintzer P.,
Frimberger A. E.,
MorrisonCollister K. E.,
Wood C. A.,
Moore A. S.
Publication year - 2003
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5810.2003.00024.x
Subject(s) - ifosfamide , doxorubicin , medicine , neutropenia , chemotherapy , surgery , beagle , gastroenterology , cisplatin
A retrospective analysis was done to assess the toxicity and efficacy associated with an alternating chemotherapy protocol of ifosfamide (375 mg m −2 ) and doxorubicin (30 mg m −2 ) for adjuvant treatment of 39 dogs with sarcomas. Twelve dogs had various soft‐tissue sarcomas and 27 dogs had hemangiosarcoma (HSA). Complete blood counts were evaluated 7 days after the first dose of ifosfamide and doxorubicin. One dog had grade 4 neutropenia (<500 µL −1 ) after treatment with ifosfamide and one dog had grade 3 neutropenia (500–1000 µL −1 ) after treatment with doxorubicin. One dog treated with doxorubicin was hospitalized for 24 h due to vomiting. The median survival time (ST) for the 27 dogs with HSA treated by surgery and with doxorubicin/ifosfamide was 149 days (mean 366 days). Although the protocol of alternating ifosfamide and doxorubicin was well tolerated, it failed to result in a statistically significant improvement in the ST when compared to a historical population of dogs with stage 2 splenic HSA treated by surgery alone.